Successful treatment of monoclonal, aggressive Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia.
Perkkiö
M
M
Department of Pediatrics, Kuopio University Hospital, Finland. mikko.perkkio@kuh.fi
Riikonen
P
P
Seuri
R
R
Vornanen
M
M
D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D008727:Methotrexate